The rise of copyright’s blockbuster initially fueled a boom for pharma, nevertheless recent shifts present a murky outlook for investors. Off-patent competitors are reducing revenue, and ongoing patent challenges add https://zoyaoxqu405321.slypage.com/41741742/the-blue-pill-and-big-pharma-a-risky-play